Biomedical and Market Issues Surrounding the Advent of Biosimilars
نویسندگان
چکیده
As the patents associated with the biologics are set to expire in the near future, a new type of therapy appears on the horizon, and it is quite similar to the biologics. This commentary examines the biomedical and market issues surrounding the advent of biosimilars.
منابع مشابه
Biosimilar therapeutics—what do we need to consider?
Patents for the first generation of approved biopharmaceuticals have either expired or are about to expire. Thus the market is opening for generic versions, referred to as 'biosimilars' (European Union) or 'follow-on protein products' (United States). Healthcare professionals need to understand the critical issues surrounding the use of biosimilars to make informed treatment decisions.The compl...
متن کاملThe Role of Urban Villages in the Development of Surrounding Villages
From the past to the present time, in all civilizations and countries, urbanization is considered the most striking evolution of human societies. With the advent of the industrial revolution and the rapid expansion of cities, societies were faced with numerous problems. One of the most significant problems is Extreme centralization in one city or more and fragmentation of urban hierarchical sys...
متن کاملThe Role of Urban Villages in the Development of Surrounding Villages
From the past to the present time, in all civilizations and countries, urbanization is considered the most striking evolution of human societies. With the advent of the industrial revolution and the rapid expansion of cities, societies were faced with numerous problems. One of the most significant problems is Extreme centralization in one city or more and fragmentation of urban hierarchical sys...
متن کاملThe economics of biosimilars.
BACKGROUND The high cost of pharmaceuticals, especially biologics, has become an important issue in the battle to control healthcare costs. The Hatch-Waxman Act encourages generic competition but still provides incentives for pioneers to develop new drugs. The Biologics Price Competition and Innovation Act is intended to do the same for biologics and biosimilars. OBJECTIVE To examine informat...
متن کاملBiosimilars and the European experience: implications for the United States.
Biologics are medicines derived from a biological source. Their high prices and rapid uptake have raised hopes that with the gradual expiration of patents on the first generations of biologics, the advent of lower-cost follow-on products known as biosimilars will help "bend the cost curve." Although biosimilars have been available since 2006 within the European Union and are expected to save $1...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 6 شماره
صفحات -
تاریخ انتشار 2016